Jefferies Upgrades Regeneron Pharma (REGN) to Buy

Jefferies upgraded Regeneron Pharma (NASDAQ: REGN) from Hold to Buy with a price target of $75 (from $66).

The firm comments, "We are upgrading REGN to Buy from Hold with a new $75 PT (v $66 prev). As the dust settles around Eylea’s approval, pricing and competition, we conducted a proprietary ophthalmologist survey which predicts a more robust Eylea adoption. While our opinion remains unchanged on Eylea's profile v Lucentis, we raise our U.S. sales ests to reflect greater mkt penetration."

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $60.94 yesterday, with a 52 week range of $32.32-$79.90.

---

Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!

You May Also Be Interested In

• UPDATE: Williams Financial Group Upgrades Semtech Corp. (SMTC) to Buy; Check Again...Quarter Was Fairly Strong
• Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
• UPDATE: UBS Upgrades Assured Guaranty (AGO) to Buy; Opportunity Opens After Recent Dip on Moody's Review

Create E-mail Alert Related Categories

Upgrades

Related Entities

Jefferies & Co

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter